CTMX Stock Forecast: CytomX Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for CytomX Therapeutics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CytomX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (74): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (15): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CTMX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CTMX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | JP Morgan | Maintains | Overweight | $11 → $12 |
| 6 Nov 2026 | Wedbush | Maintains | Outperform | $11 → $12 |
| 13 Aug 2026 | JP Morgan | Maintains | Overweight | $12 → $11 |
| 10 Aug 2026 | Guggenheim | Maintains | Buy | $15 → $14 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $17 → $11 |
| 23 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 19 Mar 2026 | Barclays | Maintains | Overweight | — |
| 18 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 18 Mar 2026 | Jefferies | Maintains | Buy | — |
| 17 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Mar 2026 | JP Morgan | Upgrade | Overweight | — |
| 9 Mar 2026 | Guggenheim | Reiterates | Buy | — |
| 4 Feb 2026 | Barclays | Maintains | Overweight | — |
| 4 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 20 Jan 2026 | Barclays | Maintains | Overweight | — |
| 20 Jan 2026 | Guggenheim | Initiates | Buy | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Oct 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTMX.
This page is one stock. Monday covers all of them.
CTMX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CTMX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, CytomX Therapeutics, Inc. returned −46.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CTMX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 33.3×
- Price / book
- 1.6×
- EV / EBITDA
- —
Cheaper than 6% of US stocks
Cheaper than 51% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −43.6%
- Return on assets
- −22.7%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CytomX Therapeutics, Inc. has a market value of $446.9M and an enterprise value of $103.3M.
Revenue in the twelve months to 30 June 2026: $18.3M. The latest quarter shrank 92.4% year on year.
Net income over the same four quarters: −$79.7M, a −435.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$82.5M.
CytomX Therapeutics, Inc. employs 69 people — $265K of revenue per employee.
Data provided by Twelve Data
CTMX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CTMX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CytomX Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CTMX
What is the CTMX stock price forecast for 2026-2027?
The median 12-month analyst price target for CytomX Therapeutics, Inc. is $12, with estimates ranging from $5 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CTMX stock a buy right now?
Of the 8 analysts covering CytomX Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytomX Therapeutics, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CTMX?
As at 21 Nov 2026, CytomX Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (74 of 100).
Will CTMX stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts is $12, and Ticker Nerd's factor model ranks CytomX Therapeutics, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CTMX stock forecast for 2030?
No analyst covering CytomX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $16 over the next 12 months.
How has CTMX stock performed over the past year?
CytomX Therapeutics, Inc. returned -46.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue. Its current pipeline spans multiple cancer-focused modalities, including antibody-drug conjugates, T-cell engagers, and immune-modulating therapies such as cytokines. CytomX Therapeutics also advances programs aimed at difficult-to-treat tumors, supporting research and development across a range of solid-tumor indications. Headquartered in South San Francisco, California, CytomX Therapeutics plays a specialized role in the biotechnology market as a developer of targeted cancer therapeutics designed for precision and selectivity.
CEO Dr. Sean A. McCarthy DPHIL · 69 employees · United States · https://www.cytomx.com